Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2016

Open Access 01-12-2016 | Research article

Effect of turmeric on colon histology, body weight, ulcer, IL-23, MPO and glutathione in acetic-acid-induced inflammatory bowel disease in rats

Authors: Salim M. A. Bastaki, Mohammed Majed Al Ahmed, Ahmed Al Zaabi, Naheed Amir, Ernest Adeghate

Published in: BMC Complementary Medicine and Therapies | Issue 1/2016

Login to get access

Abstract

Background

This study investigates the protective effects of turmeric (Curcuma longa, CL) on acetic acid-induced colitis in rats.

Method

Inflammatory bowel disease (IBD) was induced in male Wistar rats by intra-rectal administration of 1 ml of 4 % acetic acid at 8 cm proximal to the anus for 30 s. Curcuma longa (CL) powder, (1, 10, or 100 mg/kg/day) was administered for either 3 days before or after IBD for 7 days. The body weight, macroscopic and microscopic analysis of the colon of CL-treated IBD rats and that of control rats (no IBD, no CL) were performed on 0 day, 2, 4 and 7th day. Myeloperoxidase (MPO), IL-23 and glutathione levels in control, untreated and treated rats were measured by ELISA.

Results

CL significantly (P < 0.05) improved IBD-induced reduction in mean body weight and mean macroscopic ulcer score. Administration of CL also significantly (P < 0.01) reduced the mean microscopic ulcer score when compared to untreated IBD control. Intake of CL by rats resulted in a significant (P < 0.05) increase in the mean serum glutathione level compared to untreated control. CL reduced both MPO and IL-23 levels in the colonic mucosa of the rat.

Conclusion

CL improved body weight gain, mean macroscopic and microscopic ulcer scores in the colon of rats suffering from acetic acid-induced IBD. CL reduced both MPO and IL-23 in the mucosa of the colon. The increase in the mean serum glutathione level may help in the reduction of oxidative stress associated with IBD.
Literature
1.
Kirsner JB, Shorter RG. Inflammatory bowel disease. 3rd ed. Philadelphia: Lea and Fibiger; 1988.
2.
Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am. 1995;24:475–507.PubMed
3.
4.
Simpson SJ, Shah S, Comiskey M, de Jong YP, Wang B, Mizoguchi E, Bhan AK, Terhorst C. T cell-mediated pathology in two model s of experimental colitis depends predominately on the interleukin 12/signal transducer and activator of transcription (STAT)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med. 1998;187:1225–34.CrossRefPubMedPubMedCentral
5.
Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281–90.CrossRefPubMed
6.
Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine IL-23 with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–25.CrossRefPubMed
7.
Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359–70.CrossRefPubMed
8.
Kullberg MC, Jankovic D, Feng CG, et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med. 2006;203:2485–94.CrossRefPubMedPubMedCentral
9.
Schmidt C, Giese T, Ludwig B, et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-23p28 in Crohn’s disease but not in ulcerative colitis. Inflamm Bowel Dis. 2005;11:16–23.CrossRefPubMed
10.
Holtta V, Klemetti P, Siponnen T, et al. IL-23/Il-17 immunity as a hallmark of Crohn’s disease. Inflamm Bowel Dis. 2008;14:1175–84.CrossRefPubMed
11.
Saruta M, Yu QT, Fleshner PR, et al. Characterization of FOXP3 + CD4+ regulatory T cells in Crohn’s disease. Clin Immunol. 2007;125:281–90.CrossRefPubMed
12.
13.
Sharma S, Strutzman JD, Kellof GJ, Steele VE. Screening of potential chemotherapeutic agents using biochemical markers of carcinogenesis. Cancer Res. 1994;54:5848–55.PubMed
14.
Ploto A. Turmeric: post-production management for improved market access for herbs and spices-turmeric. Rome: Food and Agricultural Organization of the United Nations (FAO); 2003.
15.
16.
Cooper TH, Clarke G, Guzinski J. Teas, spices and herbs. In: Food Phytochemicals, ed. Ho, CT Vol. I pp 231–236, Washington, DC: American Chemical Society; 1994.
17.
Chuang SE, Cheng AL, Lin JK, Kuo ML. Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol. 2000;38:991–5.CrossRefPubMed
18.
Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, Fang YX. Preventive and therapeutic effects of NF-kappa B inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol. 2005;11:1747–52.CrossRefPubMedPubMedCentral
19.
Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK. Curcumin, the major component of food flavorturmeric, reduces mucosal injury in trinitrobenzene sulphonic acid induced colitis. Br J Pharmacol. 2003;139:209–18.CrossRefPubMedPubMedCentral
20.
Aldini R, Budriesi R, Roda G, Micucci M, Ioan P, D’Errico-Grigioni A, Sartini A, Guidetti E, Marocchi M, Cevenini M, Rosini F, Montagnani M, Chiarini A, Mazzella G. Curcuma longa extract exerts a myorelaxant effect on the ileum and colon in a mouse experimental colitis model, independent of the anti-inflammatory effect. PLoS One. 2012;7:e44650.CrossRefPubMedPubMedCentral
21.
Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am I Physiol. 1990;258:G527–34.
22.
Silk DBA, Payne-James J. Inflammatory bowel disease: nutritional implications and treatment. Proc Nutr Soc. 1989;48:355–61.CrossRefPubMed
23.
Eiden KA. Nutritional consideration in inflammatory bowel disease. Pract Gastroenterol. 2003;17:67–9.
24.
Gassull MA. Nutritional consideration in inflammatory bowel disease: its relation to pathophysiology, outcome and therapy. Dig Dis. 2003;21:220–7.CrossRefPubMed
25.
Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795–803.CrossRefPubMed
26.
Lanfranchi GA, Brignola C, Campieri M, Bazzocchi G, Pasquali R, Bassein L, Labò G. Assessment of nutritional status in Crohn’s disease in remission or low activity. Hepatogastroenterology. 1984;31:129–32.PubMed
27.
Mijac D, Janković GLJ, Jorga J, Krtić MN. Nutritional status in patients with active inflammatory bowel disease: Prevalence of malnutrition and methods for nutritional assessment. Eur J Int Med. 2010;21:315–9.CrossRef
28.
Jeejeebhoy KN. Clinical nutrition: management of nutritional problems in of patients with Crohn’s disease. CMAJ. 2002;166:913–8.PubMedPubMedCentral
29.
Goh J, O’Morain CA. Nutrition and adult inflammatory bowel disease Review article. Alim Pharmacol Ther. 2003;17:307–20.CrossRef
30.
Powell-Tuck J, Hennessy EM. A comparison of mid upper arm circumference, body mass index and weight loss as indices of undernutrition in acutely hospitalized patients. Clin Nutr. 2003;22:307–12.CrossRefPubMed
31.
Klein S, Meyers S, O’Sullivan P, Barton D, Leleiko N, Janovitz HD. The metabolic impact of active ulcerative colitis. Energy expenditure and nitrogen balance. J Clin Gastroenterol. 1988;10:34–40.CrossRefPubMed
32.
Ballinger AB, Azooz Q, El-Haj T, Poole S, Farthing MJ. Growth failure occurs through a decrease in insulin-like-growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut. 2000;46:694–700.CrossRefPubMedPubMedCentral
33.
Liju VB, Jeena K, Kuttan R. An evaluation of antioxidant, anti-inflammatory, and antinociceptive activities of essential oil from Curcuma longa L. Indian J Pharmacol. 2011;43(5):526–31.CrossRefPubMedPubMedCentral
34.
Salh B, Assi K, Templeman V, Parhar K, Owen D. Curcumin attenuates DNB-induced murine colitis. Am J Gastrointest Liver Physiol. 2003;285:G235–43.CrossRef
35.
Topcu-Tarladacalisir Y, Akpolat M, Uz YH, Kizilay G, Sapmaz-Metin M. Cerkezkayabekir, Omurlu IK. Effects of curcumin on apoptosis and oxidoinflammatory regulation in a rat model of acetic acid-induced colitis: the roles of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. J Med Food. 2013;16(4):296–305.CrossRefPubMed
36.
Funk JL, Frye JB, Oyarzo JN, Kuscuoglu N, Wilson J, McCaffrey G, Stafford G, Chen G, Lantz RC, Jolad SD, Sólyom AM, Kiela PR, Timmermann BN. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum. 2006;54(11):3452–64.CrossRefPubMed
37.
Funk JL, Oyarzo JN, Frye JB, Chen G, Lantz RC, Jolad SD, Sólyom AM, Timmermann BN. Turmeric extracts containing curcominoids prevent experimental rheumatoid arthritis. J Nat Med. 2006;69(3):351–5.
38.
Rao CV. Turmeric natural COX 2 inhibitor. Adv Exp Med Biol. 2006;595:213–6.CrossRef
39.
Deshpande SS, Lalitha VS, Ingle AD, Raste AS, Gadre SG, Maru GB. Subchronic oral toxicity of turmeric and ethanolic turmeric extract in female mice and rats. Toxicol Lett. 1998;95(3):183–93.CrossRefPubMed
40.
Bille N, Larsen JC, Hansen EV, Würtzen G. Subchronic oral toxicity of turmeric oleoresin in pigs. Food Chem Toxicol. 1985;23(11):967–73.CrossRefPubMed
41.
Yamada T, Zimmerman BJ, Specian RD, Grisham MB. Role of neutrophils in acetic acid-induced colitis in rats. Inflammation. 1991;15(5):399–411.CrossRefPubMed
42.
Millar AD, Rampton DS, Chander CL, Claxson AWD, Blades S, Coumbe A, Panetta J, Morris CJ, Blake DR. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 1996;39:407–15.CrossRefPubMedPubMedCentral
43.
El-Abhar HS, Hammad LN, Gawad HS. Modulating effect of ginger extract on rats with ulcerative colitis. J Ethnopharmacol. 2008;118(3):367–72.CrossRefPubMed
44.
Singh G, Kapoor IP, Singh P, de Heluani CS, de Lampasona MP, Catalan CA. Comparative study and chemical composition and antioxidant activity of fresh and dry rhizomes of turmeric (Curcuma longa Linn.). Food Chem Toxicol. 2010;48:1026–31.CrossRefPubMed
45.
Camacho-Barquero L, Villegas I, Sάnchez-Calvo JM, Talero E, Sanchez-Fidalgo S, Motilva V. Alarcón de la Lastra C. Curcumin. A Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol. 2007;3:333–42.CrossRef
46.
Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T, Koide Y. Curcumin prevents and ameliorates trinitrobenzenesulfonic acid-induced colitis in mice. Gastroenterology. 2002;123:1912–22.CrossRefPubMed
47.
Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191–3.CrossRefPubMed
48.
Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloylmethane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986;24:651–4.PubMed
49.
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502–6.CrossRefPubMed
50.
Ramadan G. Al–Kahtani MA, El-Sayed. Anti-inflammatory and anti-oxidant properties of Curcuma longa (turmeric versus Zingiber officinale (ginger) rhizomes in rat adjuvant-induced arthritis. Inflammation. 2011;34(4):291–301.CrossRefPubMed
51.
52.
Pockros PJ, Foroozan P. Golytely lavage versus a standard colonoscopy preparations. Effect on normal colonic mucosal histology. Gastroenterology. 1985;88:545–8.CrossRefPubMed
53.
Greenson JK, Stern RA, Carpenter SL, Barnett JL. The clinical significance of focal active colitis. Hum Pathol. 1997;28:729–33.CrossRefPubMed
54.
Zwas FR, Nicholas W, Cirillo DE, Eisen RN. Colonic mucosal abnormalities with oral sodium phosphate solution. Gastrointest Endosc. 1996;43:463–6.CrossRefPubMed
55.
Kruidenier L, Verspaget HW. Oxidative stress as a pathogenic factor in inflammatory bowel disease — radicals or ridiculous? Alim Pharmacol Ther. 2002;16:1997–2015.CrossRef
56.
57.
Yamada T, Grisham MB. Role of neutrophil–derived oxidants in the pathogenesis of intestinal inflammation. Klin Wochenschr. 1991;69(21–23):988–94.CrossRefPubMed
58.
Sido B, Hack V, Hochlehner A, Lipps H, Herfarth C, Droge W. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut. 1998;42:485–92.CrossRefPubMedPubMedCentral
59.
Tobler A, Koeffler HP. Myeloperoxidase: localization, structure and function. In: Harris JR, editor. Blood Cell Biochemistry. 3rd ed. New York: Plenum; 1991. p. 255.CrossRef
60.
Clarke RA, Borregaard N. Neutrophils autoinactivate secretory products by myeloperoxidase-catalyzed oxidation. Blood. 1985;65:375.
Metadata
Title
Effect of turmeric on colon histology, body weight, ulcer, IL-23, MPO and glutathione in acetic-acid-induced inflammatory bowel disease in rats
Authors
Salim M. A. Bastaki
Mohammed Majed Al Ahmed
Ahmed Al Zaabi
Naheed Amir
Ernest Adeghate
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2016
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-016-1057-5

Other articles of this Issue 1/2016

BMC Complementary Medicine and Therapies 1/2016 Go to the issue

Research article

Synergistic effects and related bioactive mechanism of Potentilla fruticosa L. leaves combined with Ginkgo biloba extracts studied with microbial test system (MTS)

Research article

Anti-inflammatory and in-vitro antibacterial activities of Traditional Chinese Medicine Formula Qingdaisan

Research article

Using auriculotherapy for osteoarthritic knee among elders: a double-blinded randomised feasibility study

Research article

Herbal medicine use behaviour in Australian adults who experience anxiety: a descriptive study

Research article

Effect of SQW on the bladder function of mice lacking TRPV1

Research article

Inhibitory action on the production of advanced glycation end products (AGEs) and suppression of free radicals in vitro by a Sri Lankan polyherbal formulation Nawarathne Kalka